Hyperoncotic Albumin Solution in Continuous Renal Replacement Therapy Patients.

ABSTRACT:

Aim

The aim of this study was to investigate the association of hyperoncotic (20%) human albumin solution (HAS) with outcomes among critically ill patients receiving continuous renal replacement therapy (RRT).

Methods

Analysis of the Randomized Evaluation of Normal versus Augmented Level (RENAL) RRT trial data.

Results

Of 1,508 patients, 771 (51%) received albumin. Of these, 345 (45%) received 4% HAS only, 155 (20%) received 20% HAS only, and 271 (35%) received both. Patients who received combined 4% and 20% HAS were more severely ill, received more days of RENAL trial therapy and required mechanical ventilation for longer. Mean daily fluid balance was -288 mL (-904 to 261) with 20% HAS only versus 245 mL (-248 to 1,050) with 4% HAS only (p < 0.001). On Cox proportion

SUBMITTER: O'Brien Z 

PROVIDER: S-EPMC9393816 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature